Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $23.34, but opened at $24.36. Dianthus Therapeutics shares last traded at $23.94, with a volume of 9,679 shares trading hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on DNTH shares. Jefferies Financial Group upped their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 22nd. Raymond James raised their price target on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an "outperform" rating in a report on Thursday. Wedbush increased their price objective on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an "outperform" rating in a research report on Friday, March 22nd. Finally, Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They set a "buy" rating and a $44.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $42.40.
Check Out Our Latest Report on DNTH
Dianthus Therapeutics Price Performance
The company's 50 day moving average is $25.83 and its 200 day moving average is $17.16.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Dianthus Therapeutics
Several hedge funds have recently bought and sold shares of DNTH. FMR LLC bought a new position in Dianthus Therapeutics in the third quarter valued at approximately $28,961,000. Avidity Partners Management LP bought a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $16,644,000. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth $3,240,000. Vestal Point Capital LP bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $1,404,000. Finally, Vanguard Group Inc. acquired a new stake in Dianthus Therapeutics in the third quarter valued at about $1,734,000. 47.53% of the stock is owned by institutional investors.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
